Professor Richeldi treatment initiation
Leading pulmonologist Professor Richeldi discusses why early initiation of treatment in Idiopathic Pulmonary Fibrosis is important.
Search
importance of velcro-like crackles in IPF diagnosis
Dr. Bonella, Rare Lung Disease Specialist, discusses the importance of accurate & early diagnosis inIdiopathic Pulmonary Fibrosis
L'Arte di Respirare IN IPF
Expert Prof. Richeldi discusses the link between Idiopathic Pulmonary Fibrosis (IPF) and Leonardo da Vinci and importance of taking action early.
Harold and Dorothy – Full Story
T2D and CVD animation the full story – learn about the relationship between type 2 diabetes and cardiovascular disease
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Giving Life a Chance
The Angels initiative honours stroke units and the everyday heroes making a difference for stroke patients
Making Every Second Count
The Angels initiative honours emergency response teams making a difference for stroke patients
Saving Lives
The Angels initiative honours nurses saving lives one grandpa at a time
Angels Initiative in South Africa
Dr Stacey Rossouw explains how the Angels initiative is making a difference in South Africa and optimizing stroke care
IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Randye’s Story
Randye Kaye’s son, Ben, has schizophrenia. In this video we hear about her experiences and hopes for brain research, as she talks to Dr Michael Sand from Boehringer Ingelheim
Win Fight Against Cancer
At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
Collaboration in Oncology
Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.
Leading Science in Oncology
As the oncology community learns more about the complexity of tumor biology, we are discovering new and exciting therapeutic opportunities.
NeO - smart and sustainable vaccines
The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Meet BIs Brains Michael Sand
Dr. Michael Sand, Senior Clinical Program Leader, CNS at Boehringer Ingelheim shares his view on the complexities of the CNS research landscape.
A Unique Bond: a brotherhood like no other
After being diagnosed with diabetes, Eric’s unique bonds with Peetey and Jake meant they could run miles across the Idaho wilderness.
A Unique Bond: friends in need
After suffering from a stroke, Phil’s connection with Valle helped change his life
A Unique Bond: by my side
Caroline’s remarkable bond with Snowball helped her cope better with COPD and maintain a more independent life.
A Unique Bond: human and animal health
At Boehringer Ingelheim we are dedicated to animal and human health. We celebrate the truly unique bonds between people and their pets.
We’re All In
Watch our video to learn about our approach to innovation and partnerships
Telling my story AF and DVT PE Patient Voices
Telling my story AF and DVT PE Patient Voices
Practical Advice
Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
What are lay summaries
Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.